Exenatide as an adjunct to nicotine patch for smoking cessation and prevention of postcessation weight gain among treatment-seeking smokers with pre-diabetes and/or overweight: study protocol for a randomised, placebo-controlled clinical trial
This report describes the design of a double-blind, placebo-controlled, randomised clinical trial that evaluates the effects of the GLP-1RA exenatide as an adjunct to nicotine patches on smoking abstinence and PCWG.
Methods and analysis
The study will be conducted at two university-affiliated research sites in Houston, Texas, the UTHealth Center for Neurobehavioral Research on Addiction and Baylor College of Medicine Michael E. DeBakey VA Medical Centre. The sample will consist of 216 treatment-seeking smokers with pre-diabetes (haemoglobin A1c of 5.7%–6.4%) and/or overweight (body mass index of 25 kg/m2 or above). ...
Source: BMJ Open - June 14, 2023 Category: General Medicine Authors: Yammine, L., Verrico, C. D., Versace, F., Webber, H. E., Suchting, R., Weaver, M. F., Kosten, T. R., Alibhai, H., Cinciripini, P. M., Lane, S. D., Schmitz, J. M. Tags: Open access, Smoking and tobacco Source Type: research
The effect of exenatide (a GLP-1 analogue) and sitagliptin (a DPP-4 inhibitor) on asymmetric dimethylarginine (ADMA) metabolism and selected biomarkers of cardiac fibrosis in rats with fructose-induced metabolic syndrome
Biochem Pharmacol. 2023 Jun 6:115637. doi: 10.1016/j.bcp.2023.115637. Online ahead of print.ABSTRACTAsymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide (NO) synthesis, is a risk factor for endothelial dysfunction, a common pathophysiological denominator for both atherogenesis and cardiac fibrosis. We aimed to investigate whether the cardioprotective and antifibrotic effects of incretin drugs, exenatide and sitagliptin, may be associated with their ability to affect circulating and cardiac ADMA metabolism. Normal and fructose-fed rats were treated with sitagliptin (5.0/10 mg/kg) or exenatide (5/10 µ...
Source: Biochemical Pharmacology - June 8, 2023 Category: Drugs & Pharmacology Authors: G W ójcicka A Pradiuch E Fornal A Stachniuk A Korolczuk B Marzec-Kotarska H Nikolaichuk G Czechowska A Kozub A Trzpil A G óralczyk J Be łtowski Source Type: research
The effect of exenatide (a GLP-1 analogue) and sitagliptin (a DPP-4 inhibitor) on asymmetric dimethylarginine (ADMA) metabolism and selected biomarkers of cardiac fibrosis in rats with fructose-induced metabolic syndrome
Biochem Pharmacol. 2023 Jun 6:115637. doi: 10.1016/j.bcp.2023.115637. Online ahead of print.ABSTRACTAsymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide (NO) synthesis, is a risk factor for endothelial dysfunction, a common pathophysiological denominator for both atherogenesis and cardiac fibrosis. We aimed to investigate whether the cardioprotective and antifibrotic effects of incretin drugs, exenatide and sitagliptin, may be associated with their ability to affect circulating and cardiac ADMA metabolism. Normal and fructose-fed rats were treated with sitagliptin (5.0/10 mg/kg) or exenatide (5/10 µ...
Source: Biochemical Pharmacology - June 8, 2023 Category: Drugs & Pharmacology Authors: G W ójcicka A Pradiuch E Fornal A Stachniuk A Korolczuk B Marzec-Kotarska H Nikolaichuk G Czechowska A Kozub A Trzpil A G óralczyk J Be łtowski Source Type: research
The effect of exenatide (a GLP-1 analogue) and sitagliptin (a DPP-4 inhibitor) on asymmetric dimethylarginine (ADMA) metabolism and selected biomarkers of cardiac fibrosis in rats with fructose-induced metabolic syndrome
Biochem Pharmacol. 2023 Jun 6:115637. doi: 10.1016/j.bcp.2023.115637. Online ahead of print.ABSTRACTAsymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide (NO) synthesis, is a risk factor for endothelial dysfunction, a common pathophysiological denominator for both atherogenesis and cardiac fibrosis. We aimed to investigate whether the cardioprotective and antifibrotic effects of incretin drugs, exenatide and sitagliptin, may be associated with their ability to affect circulating and cardiac ADMA metabolism. Normal and fructose-fed rats were treated with sitagliptin (5.0/10 mg/kg) or exenatide (5/10 µ...
Source: Biochemical Pharmacology - June 8, 2023 Category: Drugs & Pharmacology Authors: G W ójcicka A Pradiuch E Fornal A Stachniuk A Korolczuk B Marzec-Kotarska H Nikolaichuk G Czechowska A Kozub A Trzpil A G óralczyk J Be łtowski Source Type: research
The effect of exenatide (a GLP-1 analogue) and sitagliptin (a DPP-4 inhibitor) on asymmetric dimethylarginine (ADMA) metabolism and selected biomarkers of cardiac fibrosis in rats with fructose-induced metabolic syndrome
Biochem Pharmacol. 2023 Jun 6:115637. doi: 10.1016/j.bcp.2023.115637. Online ahead of print.ABSTRACTAsymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide (NO) synthesis, is a risk factor for endothelial dysfunction, a common pathophysiological denominator for both atherogenesis and cardiac fibrosis. We aimed to investigate whether the cardioprotective and antifibrotic effects of incretin drugs, exenatide and sitagliptin, may be associated with their ability to affect circulating and cardiac ADMA metabolism. Normal and fructose-fed rats were treated with sitagliptin (5.0/10 mg/kg) or exenatide (5/10 µ...
Source: Biochemical Pharmacology - June 8, 2023 Category: Drugs & Pharmacology Authors: G W ójcicka A Pradiuch E Fornal A Stachniuk A Korolczuk B Marzec-Kotarska H Nikolaichuk G Czechowska A Kozub A Trzpil A G óralczyk J Be łtowski Source Type: research
Metagenomics study on taxonomic and functional change of gut microbiota in patients with obesity with PCOS treated with exenatide combination with metformin or metformin alone
Volume 39, Issue 1, December 2023 . (Source: Gynecological Endocrinology)
Source: Gynecological Endocrinology - June 8, 2023 Category: Endocrinology Authors: Jingwen Gan Jie Chen Rui-Lin Ma Yan Deng Xue-Song Ding Shi-Yang Zhu Ai-Jun Sun Source Type: research
GLP-1R agonists demonstrate potential to treat Wolfram syndrome in human preclinical models
Conclusions/interpretationOur study provides novel evidence for the beneficial effect of GLP-1R agonists on WFS1-deficient human pancreatic beta cells and neurons, suggesting that these drugs may be considered as a treatment for individuals with Wolfram syndrome.Graphical abstract (Source: Diabetologia)
Source: Diabetologia - June 7, 2023 Category: Endocrinology Source Type: research
Comparing the effectiveness of long-term use of daily and weekly glucagon-like peptide-1 receptor agonists treatments in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus: a network meta-analysis
ConclusionThe daily GLP-1RAs may be more effective in primary outcomes. And the daily semaglutide may be the most effective treatment for NAFLD and T2DM among the six interventions. (Source: Frontiers in Endocrinology)
Source: Frontiers in Endocrinology - June 5, 2023 Category: Endocrinology Source Type: research
CO64 Efficacy and Safety of Exenatide for the Treatment of Parkinson ’s Disease: A Systematic Literature Review
The positive effects of exenatide on nerve cells raise the possibility that exenatide may slow down or stop Parkinson ’s disease (PD) degeneration. The systematic literature review (SLR) aimed to identify and summarise the evidence supporting the efficacy and safety of exenatide in PD. (Source: Value in Health)
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: P. Rai, S. Kumar, S. Pandey, B. Singh Source Type: research
Effects of GLP-1 receptor agonists on neurological complications of diabetes
AbstractEmerging evidence suggests that treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) could be an interesting treatment strategy to reduce neurological complications such as stroke, cognitive impairment, and peripheral neuropathy. We performed a systematic review to examine the evidence concerning the effects of GLP-1 RAs on neurological complications of diabetes. The databases used were Pubmed, Scopus and Cochrane. We selected clinical trials which analysed the effect of GLP-1 RAs on stroke, cognitive impairment, and peripheral neuropathy. We found a total of 19 studies: 8 studies include stroke or ...
Source: Reviews in Endocrine and Metabolic Disorders - May 26, 2023 Category: Endocrinology Source Type: research
Effects of GLP-1 receptor agonists on neurological complications of diabetes
Rev Endocr Metab Disord. 2023 May 26. doi: 10.1007/s11154-023-09807-3. Online ahead of print.ABSTRACTEmerging evidence suggests that treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) could be an interesting treatment strategy to reduce neurological complications such as stroke, cognitive impairment, and peripheral neuropathy. We performed a systematic review to examine the evidence concerning the effects of GLP-1 RAs on neurological complications of diabetes. The databases used were Pubmed, Scopus and Cochrane. We selected clinical trials which analysed the effect of GLP-1 RAs on stroke, cognitive impair...
Source: ENDOCR REV - May 25, 2023 Category: Endocrinology Authors: Natalia Garc ía-Casares Guillermo Gonz ález-González Carlos de la Cruz-Cosme Francisco J Garz ón-Maldonado Carmen de Rojas-Leal Mar ía J Ariza Manuel Narv áez Miguel Ángel Barbancho Juan Antonio Garc ía-Arnés Francisco J Tinahones Source Type: research
